NHLBI SBIR/STTR Contract Topic
066 Haptoglobin Treatment to Reduce
Complications of Sickle Cell Disease
(Fast-Track proposals will be accepted)
Number of anticipated awards: 1-2
The release of hemoglobin into the circulation
contributes to morbidity and mortality in intense
hemolytic states such as sickle cell disease (SCD).
Free hemoglobin related vascular reactivity,
potentially through nitric oxide scavenging and
oxidative stress associated with the iron moiety of
heme likely result in pulmonary arterial
hypertension, stroke and the acute chest syndrome in
SCD. A glucocorticoid induced increase in
haptoglobin synthesis in animal models has
demonstrated an attenuation of the adverse clinical
effects of free hemoglobin. (J Clin Invest [2009]
119:2271-80)
In SBIR Phase I, offerors are requested to
establish a technical and scientific approach and
demonstrate the feasibility of manufacturing a human
plasma derived haptoglobin concentrate that is
representative of the known human polymorphisms. The
haptoglobin concentrate would be produced from
plasma fractionation using established methodologies
(such as Cohn or Kistler/Nitschmann methods) that
could support scale-up in production to clinically
relevant quantities.
The hypothesis to be tested in SBIR Phase II
studies is that well-characterized, infused
haptoglobin would complex with free hemoglobin and
accelerate its clearance by CD163 on macrophages.
This clearance should reduce the risk of altered
vascular reactivity due to nitric oxide binding and
similarly, reduce oxidative tissue damage mediated
by heme iron. These possible effects will be tested
in SBIR Phase II studies including a dose escalation
safety study in human volunteers including
determination of biomarkers which, if successful,
could be followed by a trial to examine a dose
response for painful events and/or the acute chest
syndrome as clinical endpoints in individuals with
SCD.
For more information, see the
FY2012 Contract Solicitation or
contact OTAC.
Return to NHLBI
contract topics.
Last Updated December 2011
|